Roche's Tecentriq cocktail hops into the FDA fast lane for another Merck showdown
admin 7th May 2018 Uncategorised 0Roche’s Tecentriq-Avastin-chemo combo may have scored a quicker trip into the first-line lung cancer arena. The triplet just won FDA priority review for previously untreated patients with advanced lung cancer, and that means it could go toe-to-toe with Merck & Co. by Sept. 5.
More: Roche's Tecentriq cocktail hops into the FDA fast lane for another Merck showdown
Source: fierce